Clinical trials of Plk1 in combination with other chemotherapeutic agents have also shown good tolerability and significant clinical activity in hematological malignancies (Liu et al., 2017; Su et al., 2022; Wei et al., 2023). The gene discussed is PLK1; the disease is hematologic disorder.